Assignee
BIO THERA SOLUTIONS LTD
CN·4 granted patents·28 pending applications·6 citations·filing 2018–2023
Top patents by PatentIndex Score
32 records- 0180US11192954B2Compounds and methods for the treatment of TROP2 positive diseasesBIO THERA SOLUTIONS LTD·Filed 2018·Granted Dec 7, 2021·3 cites·18 claims
- 0278US11505609B2Recombinant antibody having unique glycan profile produced by CHO host cell with edited genome and preparation method thereofBIO THERA SOLUTIONS LTD·Filed 2018·Granted Nov 22, 2022·3 cites·5 claims
- 0365US2023190649A1Liquid formulation of humanized antibody for treating il-6-mediated diseasesBIO THERA SOLUTIONS LTD·Filed 2022·Application pending·0 cites
- 0462US2023203169A1Recombinant antibody having unique glycan profile produced by cho host cell with edited genome and preparation method thereofBIO THERA SOLUTIONS LTD·Filed 2022·Application pending·0 cites
- 0562US2026008848A1Anti-nectin-4 antibody, and antibody-drug conjugate and use thereofBIO THERA SOLUTIONS LTD·Filed 2023·Application pending·0 cites
- 0662US2025388667A1Anti-nectin-4 antibody and use thereofBIO THERA SOLUTIONS LTD·Filed 2023·Application pending·0 cites
- 0760US2025249114A1Method for treating her2-positive solid tumorBIO THERA SOLUTIONS LTD·Filed 2023·Application pending·0 cites
- 0859US2025333498A1Anti-cldn18.2 antibody, and antibody-drug conjugate and use thereofBIO THERA SOLUTIONS LTD·Filed 2023·Application pending·0 cites
- 0958US12371491B2Anti-TIGIT immunosuppressant and application thereofBIO THERA SOLUTIONS LTD·Filed 2020·Granted Jul 29, 2025·0 cites·16 claims
- 1058US2025262316A1Antibody-drug conjugate and application thereofBIO THERA SOLUTIONS LTD·Filed 2022·Application pending·0 cites
- 1158US2025381283A1Method for treating solid tumorBIO THERA SOLUTIONS LTD·Filed 2023·Application pending·0 cites
- 1258US2025051450A1Use of anti-pd-l1/cd47 bispecific antibody in treatment of diseasesBIO THERA SOLUTIONS LTD·Filed 2022·Application pending·0 cites
- 1356US2025059274A1ANTI-FRa ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOFBIO THERA SOLUTIONS LTD·Filed 2022·Application pending·0 cites
- 1456US2024269315A1Drug conjugate and use thereofBIO THERA SOLUTIONS LTD·Filed 2022·Application pending·0 cites
- 1554US2024400690A1Anti-b7-h3 antibody and application thereofBIO THERA SOLUTIONS LTD·Filed 2022·Application pending·0 cites
- 1652US2023287126A1Anti-pd-l1 antibody and use thereofBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 1752US2024052026A1Stable antibody formulation, preparation method therefor, and applications thereofBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 1852US2023279144A1Anti-her2 antibody and use thereofBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 1952US2022071901A1A liquid formulation of humanized antibody for treating il-6-mediated diseasesBIO THERA SOLUTIONS LTD·Filed 2018·Application pending·0 cites
- 2052US2024115698A1Anti-il-5 antibody formulation, preparation method therefor and use thereofBIO THERA SOLUTIONS LTD·Filed 2022·Application pending·0 cites
- 2151US12466887B2Antibody binding to PD-1BIO THERA SOLUTIONS LTD·Filed 2020·Granted Nov 11, 2025·0 cites·12 claims
- 2251US2023416386A1Use of anti-ox40 antibody in treatment of tumor or cancerBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 2351US2024067728A1Bispecific antibody and use thereofBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 2451US2024228592A1Antibody and fusion protein for treating coronaviruses and use thereofBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 2551US2024092892A1Anti-cldn18.2 antibody, and preparation method therefor and use thereofBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 2651US2023303711A1Anti-cd47 antibody and use thereofBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 2750US2023203164A1Anti-ctla-4 monoclonal antibody, preparation method therefor, and application thereofBIO THERA SOLUTIONS LTD·Filed 2020·Application pending·0 cites
- 2848US2023173068A1ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOFBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 2948US2023139700A1Development and application of immune cell activatorBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 3047US2024002511A1Use of anti-pd-1 antibody in combination therapyBIO THERA SOLUTIONS LTD·Filed 2021·Application pending·0 cites
- 3146US2023338526A1Anti-cd20 antibody formulation and use of anti-cd20 antibody for treatment of cd20 positive diseasesBIO THERA SOLUTIONS LTD·Filed 2020·Application pending·0 cites
- 3240US2021079081A1Long-acting and low-toxic recombinant anti-vegf humanized monoclonal antibody and production method thereforBIO THERA SOLUTIONS LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BIO THERA SOLUTIONS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →